Your AI-Trained Oncology Knowledge Connection!
Results from a phase 3 trial indicated that olaparib yielded better-preserved health-related quality of life and reduced pain burden vs the control for patients with homologous recombination repair gene–altered metastatic castration-resistant prostate cancer who progressed following a prior next-generation hormonal drug.
Findings from a post-hoc analysis identified disparities in Black patients with early hormone receptor–positive breast cancer that could not be explained by early discontinuation of endocrine therapy, clinicopathologic characteristics, insurance coverage, or neighborhood deprivation index.
Breast cancer mortality could be reduced by half for patients with ATM, CHEK2, and PALB2 pathogenic variants who undergo annual MRI screenings between the ages of 30 to 35 years and annual MRI screenings and mammography for those 40 or older.
Alina Markova, MD, speaks to the mechanism of action of topical ruxolitinib INCB018424 phosphate 1.5% cream vs oral ruxolitinib and other topical therapies used in the treatment of non-sclerotic and superficially sclerotic chronic cutaneous graft-versus-host disease.
Patients with untreated, IGHV-mutated and -unmutated chronic lymphocytic leukemia experienced better overall survival and progression-free survival with ibrutinib and rituximab compared with fludarabine, cyclophosphamide, and rituximab.
Investigators used a patient-specific score to predict treatment outcomes in pediatric patients with acute myeloid leukemia, allowing them to identify who may benefit from higher-dose chemotherapy.
Final end point analysis of the GEMSTONE-301 trial confirmed that patients with stage III non–small cell lung cancer experienced significant clinical benefit and promising efficacy following consolidation therapy with sugemalimab monotherapy.
Awareness of smoking as a risk factor for bladder cancer is lower compared with other smoking-related conditions, highlighting a need for further education in urology.
Uday R. Popat, MD, spoke about how well post-transplant cyclophosphamide vs tacrolimus plus methotrexate to prevent graft-vs-host disease was performed in this trial.
Findings from the phase 2 DOMEC trial showed that although durvalumab plus olaparib was well tolerated, it missed the study’s primary end point of progression-free survival in patients with metastatic or recurrent endometrial cancer.
Results from the phase 3 CheckMate 816 trial show patients with resectable non¬–small cell lung cancer had improved event-free survival when treated with neoadjuvant nivolumab plus chemotherapy vs chemotherapy alone.
Geriatric consultations vs standard of care for patients with hematologic malignancies who were pre-frail or frail did not significantly improve survival at 1 year but did increase discussions on end-of-life goals of care.
Treatment with brexucabtagene autoleucel appears to be a cost-effective treatment for patients with relapsed/refractory mantle cell lymphoma following treatment with a Bruton tyrosine kinase inhibitor.
Tanios Bekaii-Saab, MD, details the GOZILA platform for colorectal cancer with experts Kristen Ciombor, MD, MSCI, and John Strickler, MD.
Superior post-scan disease upstaging in patients with recurrent prostate cancer was observed with 18F-rhPSMA-7.3 compared with conventional baseline imaging.
Patients with endometrial cancer who have low volumetric skeletal muscle measurements had lower 3-year overall and progression-free survival rates.
Patients with untreated unresectable or metastatic urothelial carcinoma and PD-L1 expression of 1% or more who received treatment with nivolumab and ipilimumab in the first-line setting did not experience an improved overall survival vs those getting standard-of-care chemotherapy, according to a final analysis of a phase 3 trial.
Lisa Sprod, PhD, MPH, provides perspective on a cancer-related fatigue assessment tools.
This review article written by Danielle Gentile, PhD, et al, reviews the management of cancer-related fatigue in integrative oncology.
David M. O’Malley, MD, spoke about where the future of treatment is heading for patients with endometrial cancer.
A panel of experts in stem cell transplant and cellular immunotherapy builds a lively discussion on current and emerging treatment options for the management of acute and chronic graft versus host disease.
The phase 3 ACHIEVE trial analyzed Asian patients with stage III colon cancer to determine how a 3-month treatment duration with capecitabine and oxaliplatin compared with 6 months.
Alina Markova, MD, discusses the rationale for assessing topical ruxolitinib INCB018424 phosphate 1.5% cream in patients with non-sclerotic and superficially sclerotic chronic cutaneous graft-versus-host disease.
Leukemia survivors who were adolescents or young adults had worse long-term survival outcomes vs the general population.
Although patients with stage I esophageal cancer who received early surgery had similar survival vs delayed surgery, those with stage II and III disease experienced improved outcomes.
Sunita D. Nasta, MD, gives her perspective on emerging treatments for peripheral T-cell lymphomas.
This review article written by Robert Stuver, MD, et al, reviews current and available treatments for peripheral T-cell lymphoma.
Data from a large-scale population-based case control study indicated that excessive weight could have a notably higher odds ratio of CRC risk than previously identified in epidemiologic studies.
Patients with node-positive breast cancer did not have a significant improvement in disease-free survival with the addition of internal mammary node irradiation to regional nodal irradiation; however, patients with medically or centrally located tumors could benefit.
Patients with relapsed/refractory B-cell non-Hodgkin lymphoma who experienced grade 3 or higher immune effector cell–associated neurotoxicity syndrome who were treated with early intrathecal therapy experienced improved survival.
